Clinical Studies Sponsored by MacroGenics

Clinical Studies where

Trial Sponsor

Name	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
‌ A Study of MGC026 in Participants With Advanced Solid Tumors	NCT06242470	Cervical cancer Bladder cancer Colorectal cancer Hepatocellular carcinoma Sarcoma Endometrial cancer Melanoma Clear cell renal cell carcinoma	2024	2028	Interventional
‌ Flotetuzumab Expanded Access Program	NCT04678466	Acute myeloid leukemia
‌ Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer	NCT02492711		August 24, 2015	June 14, 2022	Interventional
‌ A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults	NCT00515385		2007	2009	Interventional
‌ RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma	NCT00101972	Cancer	2004	2008	Interventional
‌ Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes	NCT01189422		2010	2011	Interventional
‌ Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer	NCT02381314	Melanoma	March 26, 2015	September 26, 2018	Interventional
‌ Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors	NCT02982941	Osteosarcoma Rhabdomyosarcoma Neuroblastoma	2016	May 22, 2019	Interventional
‌ Treatment of West Nile Virus With MGAWN1	NCT00927953	Encephalitis West Nile fever ‌ Meningitis	2009	2011	Interventional
‌ Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	NCT02152956		June 9, 2014	July 5, 2022	Interventional
‌ Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure	NCT01206504
‌ Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer	NCT00625586	Pancreatic cancer	April 15, 2008	March 18, 2009	Interventional
‌ Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer	NCT02475213	Melanoma Head and neck cancer	2015	August 18, 2021	Interventional
‌ A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy	NCT05261191		September 26, 2022	2024	Interventional
‌ MGD019 DART® Protein in Unresectable/Metastatic Cancer	NCT03761017	Colorectal cancer	December 12, 2018	2024	Interventional
‌ Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer	NCT02689284	Esophageal cancer Stomach cancer	2016	2021	Interventional
‌ MGD009/MGA012 Combination in Relapsed/Refractory Cancer	NCT03406949		February 27, 2018	April 27, 2022	Interventional
‌ A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms	NCT03219268	Cervical cancer Ovarian cancer Cholangiocarcinoma	August 18, 2017	February 8, 2023	Interventional
‌ Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer	NCT04082364		September 30, 2019	2024	Interventional
‌ Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)	NCT00870818		2009	2011	Interventional
‌ Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis	NCT00954915	Psoriasis	2009	2010	Interventional
‌ Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer	NCT01828021	‌ Breast Cancer	2013	April 14, 2017	Interventional
‌ MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer	NCT03531632	‌ Colorectal Cancer Metastatic	June 4, 2018	February 8, 2020	Interventional
‌ Safety Study of MGAH22 in HER2-positive Carcinomas	NCT01148849	‌ Breast Cancer	2010	June 14, 2022	Interventional
‌ Phase 1 Study of MGD010 in Healthy Subjects	NCT02376036		2015	2017	Interventional

Results per page:

34 results

0 selected

34 results

0 selected